Dr. Barton G. Williams, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- North Carolina Medical School (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 462
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: North Carolina Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
NC license 39527
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Novant Health New Hanover Regional Medical Center Wilmington, NC
Medical groups
- Legacy Healthcare Services Inc (3,223 clinicians)
- Wrightsville Family Practice, PA (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 462
- Services billed
- 1,731
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 544 | 307 |
| Established patient office or other outpatient visit, 20-29 minutes | 299 | 206 |
| Automated urinalysis test | 163 | 139 |
| Insertion of needle into vein for collection of blood sample | 108 | 97 |
| X-ray of chest, 2 views | 64 | 55 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 53 | 53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 38 | 38 |
| Detection test by immunoassay with direct visual observation for influenza virus | 34 | 17 |
| Administration of vaccine | 29 | 27 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 22 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 104 payments worth $2,334 in total to this clinician.
| Abbott Laboratories | $376 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $333 |
| Novo Nordisk Inc | $304 |
| AbbVie Inc. | $268 |
| Pfizer Inc. | $199 |
| Lilly USA, LLC | $169 |
| Exact Sciences Corporation | $109 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $88.67 |
| Food and Beverage | $2,334 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 3 companies. The companies reported $2,195,471 in research payments for these studies, mostly to the institutions running them.
- A phase 12 randomized doubleblinded study to evaluate the safety tolerability and immunogenicity of modified rna vaccine candidates against influenza and COVID19 in healthy individuals
Pfizer Inc. - A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age
ModernaTX, Inc. · Completed · NCT06864143 - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - A phase 3 randomized observerblinded study to evaluate the safety tolerability and immunogenicity of a combined modified rna vaccine candidate against COVID19 and influenza in healthy individuals
Pfizer Inc. - A phase 3 study to evaluate the safety tolerability and immunogenicity of a respiratory syncytial virus rsv prefusion f subunit vaccine in adults 60 years of age and older
Pfizer Inc. - A phase 3 randomized doubleblind placebocontrolled clinical study evaluating the safety tolerability immunogenicity and efficacy of a variantadapted BNT162B2 vaccine in healthy participants 50 through 64 years of age
Pfizer Inc. - Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2)
ModernaTX, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.